Evidence map›Paper›PMID 38089136›Full record

ArticleACS materials Au2023

Injectable Devices for Delivery of Liquid or Solid Protein Formulations.

Daniel A Bernards, Chu Jian Ma, Youning Zhang, Tannia M Rodriguez, John Dickson, Bhushan N Kharbikar, Robert B Bhisitkul, Tejal A Desai

Abstract read
In one paragraph

Article in ACS materials Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel A BernardsUniversity of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-8176-1690
Chu Jian MaUniversity of California, San Francisco, Department of Ophthalmology, San Francisco, California 94143, United States.
Youning ZhangUniversity of California, San Francisco, Department of Ophthalmology, San Francisco, California 94143, United States.
Tannia M RodriguezUniversity of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California 94143, United States.
John DicksonUniversity of California, San Francisco, Department of Ophthalmology, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-9958-1559
Bhushan N KharbikarUniversity of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-0394-0308
Robert B BhisitkulUniversity of California, San Francisco, Department of Ophthalmology, San Francisco, California 94143, United States.
Tejal A DesaiUniversity of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-3409-9208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sustained delivery of protein therapeutics remains a largely unsolved problem across anatomic locations. Miniaturized devices that can provide sustained delivery of protein formulations have the potential to address this challenge via minimally invasive administration. In particular, methodologies that can optimize protein formulation independent of device manufacture have the greatest potential to provide a platform suitable for wide applications. The techniques developed here demonstrate the fabrication of tubular devices for sustained release of protein therapeutics. Utilizing a dip-casting process, fine-scale tubes can be reliably produced with wall thickness down to 30 μm. Techniques were developed that enabled effective loading of either solid or liquid formulations, while maintaining a cylindrical form-factor compatible with placement in a 22-gauge needle. Further, highly compacted protein pellets that approach the expected density of the raw materials were produced with a diameter (∼300 μm) suitable for miniaturized devices. Release from a solid-loaded device was capable of sustaining release of a model protein in excess of 400 days. Given significant interest in ocular applications, intravitreal injection was demonstrated in a rabbit model with these devices. In addition, to simulate repeated injections in ocular applications, serial intravitreal injection of two devices in a rabbit model demonstrated acceptable ocular safety without significant intraocular inflammation from clinical exam and histology.

Identifiers

PMID38089136
PMCPMC10176615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.